istradefylline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
N-methylated xanthine derivatives	4882	155270-99-8

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nourianz
istradefylline
nouriast
KW-6002
KW6002

selective antagonist at the A2A receptor, used in the treatment of Parkinson's disease

Molecular weight: 384.44
Formula: C20H24N4O4
CLOGP: 3.03
LIPINSKI: 0
HAC: 8
HDO: 0
TPSA: 76.90
ALOGS: -3.33
ROTB: 6

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Aug. 27, 2019	FDA	KYOWA KIRIN
March 15, 2013	PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dyskinesia	78.15	53.56	19	213	29089	56262746
Hallucination	59.14	53.56	17	215	49132	56242703

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dyskinesia	95.29	49.89	27	495	41047	70886875
Hallucination	90.77	49.89	30	492	76230	70851692
Hallucination, visual	66.63	49.89	19	503	29318	70898604

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N04CX01	NERVOUS SYSTEM ANTI-PARKINSON DRUGS OTHER ANTIPARKINSON DRUGS Other antiparkinson drugs
MeSH PA	D058917	Adenosine A2 Receptor Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D058914	Purinergic Antagonists
MeSH PA	D058915	Purinergic P1 Receptor Antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Parkinson's disease	indication	49049000	DOID:14330

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	1.59	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
20MG	NOURIANZ	KYOWA KIRIN	N022075	Aug. 27, 2019	RX	TABLET	ORAL	7727994	Jan. 18, 2023	A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSONS DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY
40MG	NOURIANZ	KYOWA KIRIN	N022075	Aug. 27, 2019	RX	TABLET	ORAL	7727994	Jan. 18, 2023	A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSONS DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY
20MG	NOURIANZ	KYOWA KIRIN	N022075	Aug. 27, 2019	RX	TABLET	ORAL	7727993	Jan. 28, 2023	A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSONS DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY
40MG	NOURIANZ	KYOWA KIRIN	N022075	Aug. 27, 2019	RX	TABLET	ORAL	7727993	Jan. 28, 2023	A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSONS DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
20MG	NOURIANZ	KYOWA KIRIN	N022075	Aug. 27, 2019	RX	TABLET	ORAL	Aug. 27, 2024	NEW CHEMICAL ENTITY
40MG	NOURIANZ	KYOWA KIRIN	N022075	Aug. 27, 2019	RX	TABLET	ORAL	Aug. 27, 2024	NEW CHEMICAL ENTITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Adenosine receptor A2a	GPCR	P29274	AA2AR_HUMAN	ANTAGONIST	Ki	8.66		CHEMBL	SCIENTIFIC LITERATURE
Adenosine receptor A2b	GPCR	P29275	AA2BR_HUMAN		Ki	5.75		CHEMBL
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.35		CHEMBL
Adenosine receptor A1	GPCR	P30542	AA1R_HUMAN		Ki	6.08		CHEMBL
Amine oxidase [flavin-containing] B	Enzyme	P27338	AOFB_HUMAN		Ki	7.57		CHEMBL
Adenosine receptor A1	GPCR		AA1R_RAT		Ki	6.82		CHEMBL
Adenosine receptor A2a	GPCR		AA2AR_RAT		Ki	8.70		CHEMBL

External reference:

ID	Source
2GZ0LIK7T4	UNII
D04641	KEGG_DRUG
4038742	VANDF
C0673470	UMLSCUI
CHEBI:134726	CHEBI
CHEMBL431770	ChEMBL_ID
5311037	PUBCHEM_CID
DB11757	DRUGBANK_ID
8387	INN_ID
C111599	MESH_SUPPLEMENTAL_RECORD_UI
5608	IUPHAR_LIGAND_ID
2199015	RXNORM
322306	MMSL
37365	MMSL
d09365	MMSL
018108	NDDF
789546007	SNOMEDCT_US
789550000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
NOURIANZ	HUMAN PRESCRIPTION DRUG LABEL	1	42747-602	TABLET, FILM COATED	20 mg	ORAL	NDA	31 sections
NOURIANZ	HUMAN PRESCRIPTION DRUG LABEL	1	42747-604	TABLET, FILM COATED	40 mg	ORAL	NDA	31 sections